Transferrin R

Transferrin R

Transferrin R Overview

Molecule Name
Transferrin receptor protein 1
Synonyms
CD71,TFRC,TFR,sTfR,TfR1,Trfr,T9,p90
Drug Development Progress
Drugs in Clinical Trials15
Approved Drugs1
Highest Development StageApproved
Target Synonym
TFRC,T9,sTfR,Transferrin receptor protein 1,TR,Transferrin Receptor,P90,Transferrin Receptor (P90, CD71),CD71 Antigen,IMD46,CD71,TfR1,Trfr,TfR
Background
CD antigen CD71 is also known as Transferrin receptor protein 1, TfR, sTfR, p90, TfR1, Trfr, which belongs to the peptidase M28 family and M28B subfamily. CD71 /TFR contains one PA (protease associated) domain. CD71 / TfR1 is required for iron delivery from transferrin to cells. CD71 is a potential new target in cases of human leukomia & lymphoma. CD71 /TFRC / TfR has been shown to interact with GABARAP and HFE.

Transferrin R Product List

Species
  • Human(6)
  • Cynomolgus(4)
  • Mouse(4)
  • Rat(2)
Tag
  • His Tag(7)
  • His Tag & Avi Tag(4)
  • Fc Tag(3)
  • Fc Tag & Avi Tag(1)
  • Tag Free(1)
Host
  • HEK293(16)
Conjugate
  • Biotin-labeled(8)
  • Unconjugated(8)
Grade
  • RUO(16)
Low Endotoxin
  • Yes(5)
  • No(11)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
Transferrin R
Human Transferrin R / CD71 Protein, His Tag, low endotoxin (Mass Spec & MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPRBLI

$350.00

100ug
Transferrin R
Biotinylated Mouse Transferrin R / CD71 Protein, His Tag, ultra sensitivity (primary amine labeling) (MALS verified)
Mouse
HEK293
MALSSDS-PAGE
ELISA

$415.00

25ug
Transferrin R
Human Transferrin R / CD71 Protein, Fc Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$350.00

100ug
Transferrin R
Cynomoguls / Rhesus macaque Transferrin R / CD71 Protein, His Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$355.00

100ug
Transferrin R
Biotinylated Human Transferrin R / CD71 Protein, Avitag™,His Tag (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

25ug
Transferrin R
Cynomoguls / Rhesus macaque Transferrin R / CD71 Protein, Fc Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$355.00

100ug
Transferrin R
Biotinylated Cynomoguls / Rhesus macaque Transferrin R / CD71 Protein, His Tag, ultra sensitivity (primary amine labeling) (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

25ug
Transferrin R
Biotinylated Cynomoguls / Rhesus macaque Transferrin R / CD71 Protein, Avitag™,His Tag (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

25ug
Transferrin R
Human Transferrin R / CD71 Protein, Tag Free, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$415.00

100ug
Transferrin R
Biotinylated Human Transferrin R / CD71 Protein, His Tag, ultra sensitivity (primary amine labeling) (MALS verified)
Human
HEK293
MALSSDS-PAGE
ELISASPR

$360.00

25ug
You Have Viewed 1-10 Of 16 Results
  • 1
  • 2

Can’t find what you need?

Submit your requirements and our technical
team will help.

FAQ

How should species selection be planned for TfR1-targeted delivery programs?

Use human TfR1 for immunization and primary screening, then compare cynomolgus, mouse, or rat TfR1 according to the planned model. Matched construct and capture formats are essential for interpreting cross-species affinity.

Which TfR1 format helps minimize avidity bias in affinity measurements?

Tag-free or His-tagged TfR1 is generally preferred when measuring monovalent kinetics. Fc-fused TfR1 can improve stability or capture but may introduce dimerization-related avidity, so results should be confirmed with a second format.

When should I choose Avitag™-based or primary-amine biotinylated TfR1?

Avitag™ provides site-specific biotinylation and more controlled orientation for quantitative SPR, BLI, or ELISA. Primary-amine labeling can increase signal through multiple biotins but is more heterogeneous, so epitope accessibility should be verified.

How can recombinant TfR1 and a TfR1 stable cell line be combined during shuttle or antibody screening?

Recombinant TfR1 supports controlled affinity and cross-species comparisons. A TfR1 stable cell line then tests cell-surface recognition and target engagement before transcytosis-specific models are introduced.

Why can the highest-affinity TfR1 binder be a poor blood–brain barrier shuttle candidate?

TfR1-mediated transport depends on affinity, valency, and intracellular trafficking. Very tight or bivalent binding can favor receptor retention, so protein-based affinity ranking should be followed by cell transcytosis and in vivo studies.
Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Human apotransferrin (Sanquin Blood Supply Foundation)Phase 3 ClinicalSanquin Plasma Products Bv
beta-Thalassemia; Iron Metabolism Disorders
Details
Delpacibart braxlosiranAOC1020Phase 3 ClinicalAvidity Biosciences Inc
Foot-and-Mouth Disease; Muscular Dystrophies; Muscular Dystrophy, Facioscapulohumeral
Details
Delpacibart eteddesiranAOC-1001; AOC 1001Phase 3 ClinicalAvidity Biosciences Inc
Genetic Diseases, Inborn; Heredodegenerative Disorders, Nervous System; Muscular Atrophy; Muscular Diseases; Muscular Disorders, Atrophic; Muscular Dystrophies; Musculoskeletal Diseases; Myotonia; Myotonic Disorders; Myotonic Dystrophy; Nervous System Diseases; Neurodegenerative Diseases; Neuromuscular Diseases
Details
TrontinemabRO-7126209; RG-6102Phase 3 ClinicalF. Hoffmann-La Roche Ltd
Alzheimer Disease
Details
CX-2029ABBV-2029; ABBV-CX-2029; CX-2029Phase 2 ClinicalAbbvie Inc, Cytomx Therapeutics Inc
Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Solid tumours
Details
Zeleciment rostudirsenDYNE251Phase 2 ClinicalDyne Therapeutics Inc
Muscular Dystrophy, Duchenne
Details
AOC-1044AOC-1044; AOC 1044Phase 2 ClinicalAvidity Biosciences Inc
Muscular Dystrophy, Duchenne
Details
JR-446JR-446Phase 2 ClinicalJcr Pharmaceuticals Co Ltd, Medipal Holdings Corp
Mucopolysaccharidosis III
Details
JR-441JR-441Phase 2 ClinicalJcr Pharmaceuticals Co Ltd
Mucopolysaccharidosis III
Details
Lepunafusp alfaJR-171Phase 2 ClinicalJcr Pharmaceuticals Co Ltd
Mucopolysaccharidosis I
Details
PPMX-T003PPMX-T003Phase 2 ClinicalPerseus Proteomics Inc
Leukemia; Polycythemia Vera
Details
INA-03INA03Phase 1 ClinicalInatherys
Leukemia; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma
Details
PRX012-TfRPRX012-TfRPhase 1 ClinicalProthena
Alzheimer Disease
Details
KK-2260KK2260; KK-2260Phase 1 ClinicalKyowa Kirin Co Ltd
Esophageal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
Details
ABX-1100ABX-1100Phase 1 ClinicalAro Biotherapeutics Co
Glycogen Storage Disease Type II
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
Pabinafusp alfaJR-141ApprovedJcr Pharmaceuticals Co LtdJapanMucopolysaccharidosis IIJcr Pharmaceuticals Co Ltd2021-03-23
Mucopolysaccharidosis II
Details
Customer Reviews